Ketamine is a dissociative anesthetic that has several hallucinogenic effects.
A new clinical trial conducted in Australia and New Zealand has found a cheap version of ketamine is effective in treating major depression or treatment-resistant depression.
The trials were led by the University of Sydney and the Black Dog Institute, and funded by the Australian National Health and Medical Research Council.
During the trial, 179 people were given two injections of ketamine each week for a month at a clinic where they were monitored for two hours while the effects of the sedative subsided.
Trial results: One in five participants achieved total remission, while one-third of their symptoms improved by at least 50 percent.



